Total number of patients | 1322 (100.00) |
Age ≤65 years | 668 (50.53) |
Male | 760 (57.49) |
Smoking status | |
Current smoker | 612 (46.29) |
Ex-smoker | 548 (41.45) |
Never-smoker | 162 (12.25) |
COPD severity (GOLD groups) | |
A | 1 (0.08) |
B | 831 (62.86) |
C | 153 (11.57) |
D | 321 (24.28) |
Missing | 16 (1.21) |
GOLD spirometric classification | |
1 | 29 (2.19) |
2 | 569 (43.04) |
3 | 503 (38.05) |
4 | 134 (10.14) |
No preliminary examination result | 87 (6.58) |
mMRC questionnaire classification | |
Grade 0 | 51 (3.86) |
Grade 1 | 103 (7.79) |
Grade 2 | 635 (48.03) |
Grade 3 | 279 (21.10) |
Grade 4 | 238 (18.00) |
Missing | 16 (1.21) |
Exacerbations in the past 12 months | |
0 | 512 (38.73) |
1 | 405 (30.64) |
≥2 | 405 (30.64) |
≥1 exacerbation leading to hospitalisation | 161 (12.18) |
Patients with concomitant diseases | 923 (69.82) |
Cardiac disease | 634 (47.96) |
Allergic disease | 17 (1.29) |
Patient trained to use Respimat inhaler | |
No | 21 (1.59) |
Yes | 1301 (98.41) |
Pharmacologically treated for COPD in the 6 weeks prior to start of study treatment | |
No | 718 (54.31) |
Yes | 604 (45.69) |
Type of treatment for COPD in the 6 weeks prior to start of study treatment | |
Short-acting β2-agonist | 258 (19.52) |
LABA | 131 (9.91) |
Short-acting anticholinergic | 9 (0.68) |
Long-acting anticholinergic | 228 (17.25) |
Long-acting anticholinergic+LABA in fixed combination | 6 (0.45) |
Short-acting anticholinergic+short-acting β2-agonist in fixed combination | 69 (5.22) |
LABA+ICS# | 49 (3.71) |
ICS | 45 (3.40) |
Systemic corticosteroid | 5 (0.38) |
Theophylline | 6 (0.45) |
Roflumilast | 12 (0.91) |
Other | 5 (0.38) |
Missing | 2 (0.15) |